AR110967A1 - Anticuerpos miméticos fgf21 y su uso - Google Patents
Anticuerpos miméticos fgf21 y su usoInfo
- Publication number
- AR110967A1 AR110967A1 ARP180100294A ARP180100294A AR110967A1 AR 110967 A1 AR110967 A1 AR 110967A1 AR P180100294 A ARP180100294 A AR P180100294A AR P180100294 A ARP180100294 A AR P180100294A AR 110967 A1 AR110967 A1 AR 110967A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibody
- seq
- amino acid
- acid sequence
- binding fragment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Peptides Or Proteins (AREA)
Abstract
Reivindicación 1: Un anticuerpo aislado o fragmento de unión a antígeno del mismo que se une a b-klotho, en donde el anticuerpo o fragmento de unión a antígeno del mismo comprende: una CDR1 de cadena pesada (HCDR1) que comprende la secuencia de aminoácidos de SEQ ID Nº 6, 9, 10 ó 12; una CDR2 de cadena pesada (HCDR2) que comprende la secuencia de aminoácidos de SEQ ID Nº 7, 11 ó 13; una CDR3 de cadena pesada (HCDR3) que comprende la secuencia de aminoácidos de SEQ ID Nº 8 ó 14; una CDR1 de cadena ligera (LCDR1) que comprende la secuencia de aminoácidos de SEQ ID Nº 19, 31, 22 ó 25; una CDR2 de cadena ligera (LCDR2) que comprende la secuencia de aminoácidos de SEQ ID Nº 20 ó 23; y una CDR3 de cadena ligera (LCDR3) que comprende la secuencia de aminoácidos de SEQ ID Nº 21 ó 24. Reivindicación 24: Una composición farmacéutica que comprende un anticuerpo o fragmento de unión a antígeno del mismo de una de las reivindicaciones precedentes y un vehículo farmacéuticamente aceptable. Reivindicación 25: Un método para tratar un trastorno metabólico que comprende administrar a un sujeto afectado con un trastorno metabólico una cantidad eficaz de una composición farmacéutica que comprende un anticuerpo o fragmento de unión a antígeno de acuerdo con cualquiera de las reivindicaciones 1 - 23. Reivindicación 28: Un método para tratar un trastorno cardiovascular que comprende administrar a un sujeto que padece un trastorno cardiovascular una cantidad eficaz de una composición farmacéutica que comprende un anticuerpo o fragmento de acuerdo con cualquiera de las reivindicaciones anteriores. Reivindicación 43: Un método para preparar un anticuerpo o un fragmento de unión a antígeno del mismo que se une a b-klotho, que comprende la etapa de cultivar la célula huésped de la reivindicación 41 en condiciones adecuadas para la expresión del anticuerpo o un fragmento del mismo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762456609P | 2017-02-08 | 2017-02-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR110967A1 true AR110967A1 (es) | 2019-05-22 |
Family
ID=61244657
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP180100294A AR110967A1 (es) | 2017-02-08 | 2018-02-08 | Anticuerpos miméticos fgf21 y su uso |
Country Status (14)
Country | Link |
---|---|
US (3) | US10899844B2 (es) |
EP (1) | EP3580237A1 (es) |
JP (1) | JP6991246B2 (es) |
KR (1) | KR102572663B1 (es) |
CN (1) | CN110520443B (es) |
AR (1) | AR110967A1 (es) |
AU (1) | AU2018218557B9 (es) |
BR (1) | BR112019016344A2 (es) |
CA (1) | CA3052911A1 (es) |
IL (3) | IL292067B2 (es) |
MX (1) | MX2019009498A (es) |
TW (1) | TWI786087B (es) |
UY (1) | UY37598A (es) |
WO (1) | WO2018146594A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11299751B2 (en) | 2016-04-29 | 2022-04-12 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
WO2017189959A1 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
AU2020408067B2 (en) | 2019-12-20 | 2024-03-28 | Novartis Ag | Combination treatment of liver diseases using integrin inhibitors |
WO2022101853A1 (en) | 2020-11-16 | 2022-05-19 | Novartis Ag | Method of determining liver fibrosis |
WO2023125745A1 (zh) * | 2021-12-30 | 2023-07-06 | 上海津曼特生物科技有限公司 | 抗βKlotho抗体及其应用 |
Family Cites Families (116)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
US5013653A (en) | 1987-03-20 | 1991-05-07 | Creative Biomolecules, Inc. | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
DE3856559T2 (de) | 1987-05-21 | 2004-04-29 | Micromet Ag | Multifunktionelle Proteine mit vorbestimmter Zielsetzung |
US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
KR900005995A (ko) | 1988-10-31 | 1990-05-07 | 우메모또 요시마사 | 변형 인터류킨-2 및 그의 제조방법 |
ATE135370T1 (de) | 1988-12-22 | 1996-03-15 | Kirin Amgen Inc | Chemisch modifizierte granulocytenkolonie erregender faktor |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5112946A (en) | 1989-07-06 | 1992-05-12 | Repligen Corporation | Modified pf4 compositions and methods of use |
FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
WO1991006570A1 (en) | 1989-10-25 | 1991-05-16 | The University Of Melbourne | HYBRID Fc RECEPTOR MOLECULES |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
AU633698B2 (en) | 1990-01-12 | 1993-02-04 | Amgen Fremont Inc. | Generation of xenogeneic antibodies |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
US5349053A (en) | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
JP3242916B2 (ja) | 1990-12-14 | 2001-12-25 | セル ジェネシス,インコーポレイティド | レセプター関連シグナル変換系のためのキメラ鎖 |
ATE275198T1 (de) | 1991-12-02 | 2004-09-15 | Medical Res Council | Herstellung von antikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken. |
US5766886A (en) | 1991-12-13 | 1998-06-16 | Xoma Corporation | Modified antibody variable domains |
EP0746609A4 (en) | 1991-12-17 | 1997-12-17 | Genpharm Int | NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES |
US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
FR2686901A1 (fr) | 1992-01-31 | 1993-08-06 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant. |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
AU4116793A (en) | 1992-04-24 | 1993-11-29 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
DK0656946T4 (da) | 1992-08-21 | 2010-07-26 | Univ Bruxelles | Immunoglobuliner uden lette kæder |
EP0754225A4 (en) | 1993-04-26 | 2001-01-31 | Genpharm Int | HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS |
JPH08511420A (ja) | 1993-06-16 | 1996-12-03 | セルテック・セラピューテイクス・リミテッド | 抗 体 |
SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
US5834252A (en) | 1995-04-18 | 1998-11-10 | Glaxo Group Limited | End-complementary polymerase reaction |
US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
CN1117155C (zh) | 1994-07-29 | 2003-08-06 | 史密丝克莱恩比彻姆有限公司 | 新型化合物 |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
AUPO591797A0 (en) * | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
ES2258817T3 (es) | 1997-05-21 | 2006-09-01 | Biovation Limited | Metodo para la produccion de proteinas no inmunogenas. |
WO1998056906A1 (en) | 1997-06-11 | 1998-12-17 | Thoegersen Hans Christian | Trimerising module |
JP3614866B2 (ja) | 1997-06-12 | 2005-01-26 | リサーチ コーポレイション テクノロジーズ,インコーポレイティド | 人工抗体ポリペプチド |
DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
PT1071700E (pt) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
KR100940380B1 (ko) | 1999-01-15 | 2010-02-02 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
ES2571230T3 (es) | 1999-04-09 | 2016-05-24 | Kyowa Hakko Kirin Co Ltd | Procedimiento para controlar la actividad de una molécula inmunofuncional |
DE19932688B4 (de) | 1999-07-13 | 2009-10-08 | Scil Proteins Gmbh | Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen |
MXPA02001911A (es) | 1999-08-24 | 2003-07-21 | Medarex Inc | Anticuerpos ctla-4 humanos y sus usos. |
US7459540B1 (en) | 1999-09-07 | 2008-12-02 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
AU1922101A (en) | 1999-11-18 | 2001-05-30 | Chiron Corporation | Human fgf-21 gene and gene expression products |
US6716626B1 (en) | 1999-11-18 | 2004-04-06 | Chiron Corporation | Human FGF-21 nucleic acids |
EP2267026A1 (en) | 2000-04-12 | 2010-12-29 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US7943129B2 (en) | 2000-05-26 | 2011-05-17 | National Research Council Of Canada | Single-domain brain-targeting antibody fragments derived from llama antibodies |
ES2405944T3 (es) | 2000-11-30 | 2013-06-04 | Medarex, Inc. | Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas |
US20050053973A1 (en) | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
US20040175756A1 (en) | 2001-04-26 | 2004-09-09 | Avidia Research Institute | Methods for using combinatorial libraries of monomer domains |
US20050048512A1 (en) | 2001-04-26 | 2005-03-03 | Avidia Research Institute | Combinatorial libraries of monomer domains |
WO2002092780A2 (en) | 2001-05-17 | 2002-11-21 | Diversa Corporation | Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof |
AU2002337935B2 (en) | 2001-10-25 | 2008-05-01 | Genentech, Inc. | Glycoprotein compositions |
AU2003217912A1 (en) | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
DE10324447A1 (de) | 2003-05-28 | 2004-12-30 | Scil Proteins Gmbh | Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin |
EP1761561B1 (en) | 2004-01-20 | 2015-08-26 | KaloBios Pharmaceuticals, Inc. | Antibody specificity transfer using minimal essential binding determinants |
US20060008844A1 (en) | 2004-06-17 | 2006-01-12 | Avidia Research Institute | c-Met kinase binding proteins |
SI1907424T1 (sl) | 2005-07-01 | 2015-12-31 | E. R. Squibb & Sons, L.L.C. | Humana monoklonska protitelesa proti programiranem smrtnem ligandu 1 (PD-L1) |
JP5187837B2 (ja) | 2007-04-06 | 2013-04-24 | 独立行政法人産業技術総合研究所 | 補助因子による受容体の活性化方法並びにリガンド活性の利用方法 |
AU2010326024A1 (en) | 2009-12-02 | 2012-07-05 | Amgen Inc. | Binding proteins that bind to human FGFR1c, human beta-Klotho and both human FGFR1c and human beta-Klotho |
UA109888C2 (uk) | 2009-12-07 | 2015-10-26 | ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ | |
EP2558497A2 (en) | 2010-04-15 | 2013-02-20 | Amgen Inc. | Human fgf receptor and beta-klotho binding proteins |
SG190082A1 (en) | 2010-11-05 | 2013-06-28 | Covx Technologies Ireland Ltd | Anti-diabetic compounds |
EP2707718A1 (en) | 2011-05-10 | 2014-03-19 | Amgen Inc. | Method of identifying compounds that specifically modulate the interaction of fgfr1 and beta-klotho |
CN103596980B (zh) * | 2011-05-16 | 2017-08-08 | 霍夫曼-拉罗奇有限公司 | Fgfr1激动剂及使用方法 |
US9574002B2 (en) | 2011-06-06 | 2017-02-21 | Amgen Inc. | Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor |
US20140294820A1 (en) | 2011-06-24 | 2014-10-02 | University Of Miami | Fibroblast growth factor receptor inhibition for the treatment of disease |
EP2548570A1 (en) | 2011-07-19 | 2013-01-23 | Sanofi | Pharmaceutical composition for treating a metabolic syndrome |
US20140206023A1 (en) | 2013-01-24 | 2014-07-24 | Ping Gao | Methods, Kits & Antibodies for Detecting Intact Fibroblast Growth Factor 21 |
WO2014149699A1 (en) | 2013-03-15 | 2014-09-25 | Eli Lilly And Company | Bifunctional protein |
TWI728373B (zh) | 2013-12-23 | 2021-05-21 | 美商建南德克公司 | 抗體及使用方法 |
MX2016008498A (es) * | 2013-12-27 | 2016-10-07 | Chugai Pharmaceutical Co Ltd | Metodo para purificar anticuerpo que tiene bajo punto isoelectrico. |
RU2701434C2 (ru) | 2014-01-24 | 2019-09-26 | Нгм Биофармасьютикалс, Инк. | Связывающие белки и способы их применения |
WO2015148708A1 (en) * | 2014-03-25 | 2015-10-01 | Regeneron Pharmaceuticals, Inc. | Fgf21 receptor agonists and uses thereof |
WO2016054660A1 (en) | 2014-10-03 | 2016-04-07 | Surespot, Inc. | Parking assignment system with laser rangefinder and parking meter |
EP4245376A3 (en) | 2014-10-14 | 2023-12-13 | Novartis AG | Antibody molecules to pd-l1 and uses thereof |
CN108350072B (zh) | 2015-08-03 | 2022-05-24 | 诺华股份有限公司 | 治疗fgf21相关病症的方法 |
AU2016306090B2 (en) | 2015-08-11 | 2019-05-02 | Novartis Ag | 5-bromo-2,6-di-(1H-pyrazol-l-yl)pyrimidin-4-amine for use in the treatment of cancer |
-
2018
- 2018-02-06 AU AU2018218557A patent/AU2018218557B9/en active Active
- 2018-02-06 EP EP18705989.4A patent/EP3580237A1/en active Pending
- 2018-02-06 CN CN201880023256.0A patent/CN110520443B/zh active Active
- 2018-02-06 CA CA3052911A patent/CA3052911A1/en active Pending
- 2018-02-06 BR BR112019016344A patent/BR112019016344A2/pt unknown
- 2018-02-06 KR KR1020197026324A patent/KR102572663B1/ko active IP Right Grant
- 2018-02-06 MX MX2019009498A patent/MX2019009498A/es unknown
- 2018-02-06 TW TW107104076A patent/TWI786087B/zh active
- 2018-02-06 IL IL292067A patent/IL292067B2/en unknown
- 2018-02-06 JP JP2019563705A patent/JP6991246B2/ja active Active
- 2018-02-06 WO PCT/IB2018/050740 patent/WO2018146594A1/en unknown
- 2018-02-06 US US15/890,302 patent/US10899844B2/en active Active
- 2018-02-08 AR ARP180100294A patent/AR110967A1/es unknown
- 2018-02-08 UY UY0001037598A patent/UY37598A/es not_active Application Discontinuation
-
2019
- 2019-08-06 IL IL268551A patent/IL268551B/en unknown
-
2020
- 2020-12-18 US US17/127,600 patent/US11692046B2/en active Active
-
2023
- 2023-05-15 US US18/197,190 patent/US20230416407A1/en active Pending
- 2023-07-26 IL IL304781A patent/IL304781A/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20190115471A (ko) | 2019-10-11 |
AU2018218557A1 (en) | 2019-08-22 |
EP3580237A1 (en) | 2019-12-18 |
IL304781A (en) | 2023-09-01 |
TW201835103A (zh) | 2018-10-01 |
IL292067A (en) | 2022-06-01 |
WO2018146594A1 (en) | 2018-08-16 |
JP2020506728A (ja) | 2020-03-05 |
CA3052911A1 (en) | 2018-08-16 |
AU2018218557B2 (en) | 2021-05-27 |
RU2019127917A (ru) | 2021-03-09 |
US20190040153A1 (en) | 2019-02-07 |
MX2019009498A (es) | 2019-10-02 |
IL268551B (en) | 2022-05-01 |
IL268551A (en) | 2019-09-26 |
US20210171659A1 (en) | 2021-06-10 |
US11692046B2 (en) | 2023-07-04 |
CN110520443A (zh) | 2019-11-29 |
UY37598A (es) | 2018-09-28 |
IL292067B1 (en) | 2023-09-01 |
TWI786087B (zh) | 2022-12-11 |
CN110520443B (zh) | 2023-07-25 |
AU2018218557B9 (en) | 2021-06-24 |
BR112019016344A2 (pt) | 2020-04-07 |
US20230416407A1 (en) | 2023-12-28 |
IL292067B2 (en) | 2024-01-01 |
RU2019127917A3 (es) | 2021-07-01 |
US10899844B2 (en) | 2021-01-26 |
KR102572663B1 (ko) | 2023-09-01 |
JP6991246B2 (ja) | 2022-02-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR110967A1 (es) | Anticuerpos miméticos fgf21 y su uso | |
PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
PE20210132A1 (es) | Anticuerpos anti-cd3 y usos de estos | |
AR110017A1 (es) | Anticuerpos de pd-1 y usos de estos | |
AR126019A1 (es) | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación | |
PE20181921A1 (es) | NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS | |
IL277242B2 (en) | Antibodies that bind cd39 and uses thereof | |
CO6230999A2 (es) | Anticuerpo anti-esclerostina | |
PE20212088A1 (es) | Anticuerpos anti-tau y uso de los mismos | |
PE20181326A1 (es) | Anticuerpos que se unen especificamente a pd-1 y sus usos | |
PE20130226A1 (es) | Anticuerpos hacia gdf8 humano | |
CU24636B1 (es) | Anticuerpos que reconocen tau en los residuos 257-271 o 320-334 de la seq id no: 1 | |
NZ608660A (en) | Anti-cd48 antibodies and uses thereof | |
MX2019007848A (es) | Anticuerpos anti-pd-1 y usos de los mismos. | |
PE20090161A1 (es) | Anticuerpos monoclonales anti cxcl13 | |
JP2017505125A5 (es) | ||
AR110719A1 (es) | Anticuerpos humanos a la toxina hemolisina a de s. aureus | |
NZ610294A (en) | Human antibodies to human tnf-like ligand 1a (tl1a) | |
PE20142170A1 (es) | Anticuerpos frente a los ligandos del receptor b1 de bradicinina | |
PE20130817A1 (es) | Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos | |
PE20120899A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b | |
AR100573A1 (es) | Anticuerpos anti-il-17, un método para producirlos y utilizarlos | |
AR103713A1 (es) | Anticuerpos contra tau y sus usos | |
AR104906A1 (es) | Anticuerpos dirigidos a la proteína morfogenética ósea 9 (bmp9) y métodos a partir de estos | |
AR096601A1 (es) | Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso |